GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Retained Earnings

Brii Biosciences (HKSE:02137) Retained Earnings : HK$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Brii Biosciences's retained earnings for the quarter that ended in Dec. 2023 was HK$0.00 Mil.

Brii Biosciences's quarterly retained earnings declined from Dec. 2022 (HK$0.00 Mil) to Jun. 2023 (HK$-7,341.59 Mil) but then increased from Jun. 2023 (HK$-7,341.59 Mil) to Dec. 2023 (HK$0.00 Mil).


Brii Biosciences Retained Earnings Historical Data

The historical data trend for Brii Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Retained Earnings Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
- - - - -

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only - - - -7,341.59 -

Brii Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Brii Biosciences  (HKSE:02137) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Brii Biosciences (HKSE:02137) Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines